David Steinberg
Stock Analyst at Jefferies
(2.87)
# 1,572
Out of 5,148 analysts
33
Total ratings
64%
Success rate
26.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Steinberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHC Bausch Health Companies | Downgrades: Hold | $12 → $8 | $5.95 | +34.45% | 7 | Feb 6, 2025 | |
| PRGO Perrigo Company | Upgrades: Buy | $45 → $63 | $12.34 | +410.53% | 8 | Sep 30, 2021 | |
| SUPN Supernus Pharmaceuticals | Upgrades: Buy | $25 → $40 | $55.09 | -27.39% | 11 | Apr 13, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $151 → $188 | $190.46 | -1.29% | 5 | Oct 9, 2020 | |
| OCUL Ocular Therapeutix | Initiates: Buy | $8 | $10.98 | -27.14% | 1 | Mar 17, 2020 | |
| SVRA Savara | Initiates: Buy | $20 | $6.01 | +232.78% | 1 | Sep 22, 2017 |
Bausch Health Companies
Feb 6, 2025
Downgrades: Hold
Price Target: $12 → $8
Current: $5.95
Upside: +34.45%
Perrigo Company
Sep 30, 2021
Upgrades: Buy
Price Target: $45 → $63
Current: $12.34
Upside: +410.53%
Supernus Pharmaceuticals
Apr 13, 2021
Upgrades: Buy
Price Target: $25 → $40
Current: $55.09
Upside: -27.39%
Jazz Pharmaceuticals
Oct 9, 2020
Maintains: Buy
Price Target: $151 → $188
Current: $190.46
Upside: -1.29%
Ocular Therapeutix
Mar 17, 2020
Initiates: Buy
Price Target: $8
Current: $10.98
Upside: -27.14%
Savara
Sep 22, 2017
Initiates: Buy
Price Target: $20
Current: $6.01
Upside: +232.78%